REGISTER
MedJ at JSCO 2025 with Dr. Masakazu Toi
Emerging findings make MedJ at JSCO 2025 with Dr. Masakazu Toi more relevant than before. The summary connects evidence on JSCO, ADC, medj with who may benefit, what risks matter most, and how practice could change.

Masakazu Toi (President of the Japanese Breast Cancer Society), Tokyo Metropolitan Komagome Hospital, Japan

Decoding the mechanisms of ADC drugs beyond traditional therapies and their unique impact on the tumor microenvironment, charting new directions for precision treatment in breast cancer.

0
0
Loading